MoonLake Immunotherapeutics (MLTX) Q4 2023 Earnings Call

Investor webinar replay

Watch the replay and follow the connected company analysis, news, and investor updates for Moonlake Immunotherapeutics.

Watch the replay

Replay transcript excerpt

WEBVTT 00:00:00.109 -- 00:00:02.109 It's 00:00:05.053 -- 00:00:10.076 my pleasure to welcome here as well two of my colleagues, our CEO and co-founder, George 00:00:10.076 -- 00:00:15.160 Santos da Silva, our CSO and co-founder, Professor Christian Reich, and we are also joined 00:00:15.160 -- 00:00:21.145 here by two of the leading KOLs, Professor Ken Gordon and Professor Joseph Merola, 00:00:21.145 -- 00:00:27.348 who are joining us here to reflect on us with the data on the opportunity of simulation. 00:00:33.638 -- 00:00:34.499 sections. 00:00:34.499 -- 00:00:38.981 On the one hand, we will present the cirrhotic arthritis 24-weeks data. 00:00:38.981 -- 00:00:43.524 So we have a whole section dedicated to cirrhotic arthritis, one of our lead indications 00:00:43.524 -- 00:00:45.165 for sunolocumab. 00:00:45.165 -- 00:00:49.247 Then we have a whole section dedicated to the opportunity in hydrodinitis superativa, 00:00:49.247 -- 00:00:53.090 a couple of important and relevant updates also on that front. 00:00:53.090 -- 00:00:56.632 And then in the third main section, we will talk a little bit about the new frontiers 00:00:56.632 -- 00:00:58.872 for sunolocumab. 00:01:07.788 -- 00:01:12.971 Here you see the disclaimer on forward-looking statements, so please acknowledge the 00:01:12.971 -- 00:01:14.953 disclaimer. 00:01:14.953 -- 00:01:20.336 You will also have the opportunity to submit questions through the Q&A function 00:01:20.336 -- 00:01:24.098 in the webcast. Here in the room, towards the end, we will have time for a couple of 00:01:24.098 -- 00:01:26.540 questions, so then please raise your hand. 00:01:26.540 -- 00:01:30.802 The presentation will also be available as a... 00:01:33.625 -- 00:01:36.946 Please also use the Q&A function. 00:01:40.836 -- 00:01:46.0...